Eye viscosity increases with age

Article

According to a paper published in Clinical and Experimental Ophthalmology, loss of energy due to elastic hysteresis positively correlates with age, leading to the belief that eye viscosity increases with age.

According to a paper published in Clinical and Experimental Ophthalmology, loss of energy due to elastic hysteresis positively correlates with age, leading to the belief that eye viscosity increases with age.

Dr K. Ishii et al., Department of Ophthalmology, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Tokyo, Japan, included 24 eyes of 24 normal human patients in a prospective case series.

The non-contact tonometry procedure was conducted with a high-speed camera. The outcome measures were central corneal thickness (CCT), corneal thickness at 4 mm from the centre, corneal curvature and anterior chamber depth (ACD). IOP was also recorded using Goldmann applanation tonometry (GAT) and dynamic contour tonometer (DCT). The primary outcome measure was energy loss due to elastic hysteresis.

Mean CCT was 552.5 ± 36.1 µm, mean corneal curvature was 7.84 ± 0.26 mm and ACD was 2.83 ± 0.29 mm. Mean GAT-IOP was calculated as 14.2 ± 2.7 mmHg and DCT-IOP was 16.3 ± 3.5 mmHg.

The mean loss of energy due to elastic hysteresis was 3.90 × 10(-6) ± 2.49 × 10(-6) Nm and this was significantly linked to age, regardless of anterior eye structure or IOP.

The abstract for this study can be found here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.